SBIR Phase I: Single-molecule field-effect transistor arrays for multiplexed genomic identification of infectious diseases

SBIR 第一阶段：用于传染病多重基因组鉴定的单分子场效应晶体管阵列

• 批准号: 1843244
• 负责人: Steven Warren
• 金额: $ 22.5万
• 依托单位: QUICKSILVER BIOSCIENCES, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-02-01 至 2020-07-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1843244&HistoricalAwards=false
• 关键词: SBIR; Phase; Single; molecule; field

The broader impact/commercial potential of this Small Business Innovation Research Project (SBIR) project is the development of a platform for pathogen identification and other genomic applications that achieves rapid, sensitive, multiplexed single-molecule detection. The genomic diagnostics market is poised to grow to $40 billion by 2021. The goal of this platform will be to offer multiplexed detection of more than 1,000 pathogens, allowing accurate point-of-care diagnosis of infectious diseases. Other genomic applications that also are possible include assessment of the microbiome or monitoring opportunistic infections in pulmonary diseases. In addition, the platform has the potential for use in genomic sequencing, a market that is expected to reach $9 billion by 2020.The intellectual merit of this SBIR Phase I project is to develop a highly multiplexed, bioelectronic, label-free assay platform capable of real-time, label-free detection of thousands of nucleic acid targets without amplification. This will be accomplished through the use of nanoscale single-molecule field-effect transistors (smFETs) on a complementary metal-oxide semiconductor (CMOS) integrated-circuit platform, which fully leverages the economies of scale of modern semiconductor manufacturing. The initial target application for this technology is multiplexed pathogen identification at the point-of-need. This project will bring the technology to wafer-scale manufacturing, which will both improve device quality and lower the per device cost of manufacture, and demonstrate proof-of-concept for genomic detection (without amplification) on clinical samples.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这个小企业创新研究项目（SBIR）项目的更广泛的影响/商业潜力是开发一个用于病原体鉴定和其他基因组应用的平台，实现快速，灵敏，多路复用的单分子检测。 到2021年，基因组诊断市场有望增长至400亿美元。 该平台的目标是提供1,000多种病原体的多重检测，从而实现传染病的精确即时诊断。 其他可能的基因组应用包括评估微生物组或监测肺部疾病中的机会性感染。 此外，该平台还具有用于基因组测序的潜力，预计到2020年，该市场将达到90亿美元。SBIR第一阶段项目的智力价值是开发一种高度多路复用、生物电子、无标记的分析平台，能够在不扩增的情况下实时、无标记地检测数千个核酸靶点。这将通过在互补金属氧化物半导体（CMOS）集成电路平台上使用纳米级单分子场效应晶体管（smFET）来实现，该平台充分利用了现代半导体制造的规模经济。该技术的最初目标应用是在需要时进行多重病原体鉴定。该项目将把该技术应用于晶圆级制造，这将提高设备质量，降低每台设备的制造成本，并展示临床样本基因组检测（无需扩增）的概念验证。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。